BIOSYNEX: management transactions · France · AMF

About BIOSYNEX

BIOSYNEX is a French healthcare group specializing in the design, manufacturing and distribution of rapid diagnostic tests (RDTs) and, more broadly, healthcare solutions aimed at improving patient care. Founded in 2005 and headquartered in Illkirch-Graffenstaden, Alsace, the company has gradually established itself as a recognized player in in vitro diagnostics, with a commercial presence in more than 90 countries. The group employs more than 330 people and serves a broad customer base that includes medical biology laboratories, hospitals, pharmacies and other healthcare distribution channels. BIOSYNEX regularly communicates on its development strategy and financial calendar, making it a closely followed stock among healthcare small- and mid-cap investors. BIOSYNEX’s business is historically built around rapid tests, meaning medical devices designed to deliver simple, reliable and fast results at the point of care or in laboratory settings. Its product range spans multiple medical fields and is oriented toward detection, screening and monitoring across a variety of conditions. The group also emphasizes its industrial and regulatory know-how, supported by ISO 9001 and ISO 13485 certifications, which are key benchmarks in the medical diagnostics industry. Over the years, BIOSYNEX has expanded through both organic growth and acquisitions in order to strengthen its technology portfolio, geographic footprint and access to new markets. A notable part of the company’s recent history has been its financial and organizational restructuring efforts in 2024 and 2025, while continuing to develop its diagnostics activities and pharmacy division. BIOSYNEX has also completed several acquisitions and integration projects in adjacent diagnostic and healthcare businesses. These moves are intended to reinforce its position in attractive growth markets while improving its international reach and product offering. Geographically, BIOSYNEX has a strong base in France while generating a meaningful share of revenues internationally. Its business model combines product design, production and distribution, which gives it control over a full value chain in selected segments. In a demanding healthcare environment where innovation, speed of diagnosis and regulatory compliance are critical, BIOSYNEX positions itself as a specialist in rapid testing and related solutions, with the profile of a French laboratory focused on public health and faster access to diagnosis.